SACUBITRIL/VALSARTAN ESTIMATED COST SAVINGS BASED ON PARADIGM-HF RESULTS
Author(s)
Lacasa C, Figueras M, Obradors M
Novartis Farmaceutica S.A., Barcelona, Spain
Presentation Documents
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCV110
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now